Literature DB >> 1828505

Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain.

J N Joyce1, A Janowsky, K A Neve.   

Abstract

The distribution and pharmacology of the binding of [125I]epidepride, a substituted benzamide with high affinity and selectivity for dopamine (DA) D2 receptors in rat brain (Neve et al., J. Pharmacol. Exp. Ther. 252: 1108-1116, 1990), is described in human brain. Saturation analysis of the binding of [125I]epidepride to membranes derived from striatum and regions of cortex demonstrated similar Kd values (34 and 28-33 pM, respectively) but differing maximum density of binding site values (152 and 3-8 fmol/mg of protein, respectively). The pharmacological profile of binding in cortex was also similar to striatum (epidepride greater than spiperone greater than butaclamol = flupenthixol greater than clozapine) except that an additional low-affinity site, blocked by the alpha-2 adrenergic antagonist idazoxan, was present in cortex. Quantification by autoradiography also demonstrated the greatest binding in the basal ganglia, with the striatum exhibiting greater binding than the pallidal complex or midbrain regions. For the pallidum, binding in the external segment was higher than the internal segment. Within the midbrain the binding of [125I]epidepride correlated well with the known distribution of DA-containing cell bodies, with the substantia nigra (pars compacta and pars lateralis) and ventral tegmental area (A10) higher than area A8 and central gray. Binding in frontal and parietal cortex was highest in the internal layers (layers V and VI). Temporal cortex showed a 2-fold higher density of binding than other cortical regions and a trilaminar pattern; binding was greater in the external (layers I and II) and internal layers than in the middle layers (III and IV). This pattern changed in the parahippocampal complex. Within the lateral occipitotemporal cortex, binding was densest in layers I to III and very low in layers IV to VI, but binding was almost nonexistent in the adjacent entorhinal cortex. Within the hippocampal complex, binding was evident in the subiculum, CA3 and dentate gyrus and almost nonexistent in the presubiculum or other fields of the hippocampus. This pattern of binding in the parahippocampal gyrus is unique to human brain and represents sites of action for DA in limbic cortex.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828505

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.

Authors:  E C Muly; J R Votaw; J Ritchie; L L Howell
Journal:  J Pharmacol Exp Ther       Date:  2012-01-03       Impact factor: 4.030

Review 2.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

3.  SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain.

Authors:  J Kornhuber; T Brücke; P Angelberger; S Asenbaum; I Podreka
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 4.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

5.  A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.

Authors:  P Tibbo; P H Silverstone; A J McEwan; J Scott; A Joshua; K Golberg
Journal:  J Psychiatry Neurosci       Date:  1997-01       Impact factor: 6.186

6.  Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.

Authors:  Lawrence S Kegeles; Mark Slifstein; Xiaoyan Xu; Nina Urban; Judy L Thompson; Tiffany Moadel; Jill M Harkavy-Friedman; Roberto Gil; Marc Laruelle; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2010-07-31       Impact factor: 13.382

7.  Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain.

Authors:  A M Murray; H L Ryoo; E Gurevich; J N Joyce
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

8.  Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects.

Authors:  S S Wolf; T M Hyde; R C Saunders; M M Herman; D R Weinberger; J E Kleinman
Journal:  J Neural Transm Gen Sect       Date:  1995

9.  Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.

Authors:  W Pirker; T Brücke; M Riedl; M Clodi; A Luger; S Asenbaum; I Podreka; L Deecke
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Authors:  Ariel Graff-Guerrero; Matthaeus Willeit; Nathalie Ginovart; David Mamo; Romina Mizrahi; Pablo Rusjan; Irina Vitcu; Philip Seeman; Alan A Wilson; Shitij Kapur
Journal:  Hum Brain Mapp       Date:  2008-04       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.